Yigal Erlich
Fondateur chez The Yozma Group
Profil
Mr. Yigal Erlich is the founder of the Israel Venture Association and served as its Chairman in the years 1996-2002.
Between 1984 and 1992, Mr. Erlich served as the Chief Scientist of Israel's Ministry of Industry and Trade.
During his eight-year tenure as Chief Scientist, Mr. Erlich primarily directed at research and development projects of high-technology companies.
In addition, Mr. Erlich initiated the Generic Technology program, which fostered cooperation on long-term R&D activities through the creation of consortia of companies with research institutes and universities worldwide.
Mr. Erlich also started the Technology Incubator Program that led to the creation of 24 Incubation Centers throughout Israel.
Mr. Erlich was instrumental in the establishment of several bi-national industrial and technology R&D cooperation agreements with Canada, France, the Netherlands, Singapore and Spain.
Mr. Erlich was a Director of the Dead Sea Works, Israel Chemicals, Israel Oil Refineries, Hadassah's commercialization company - Hadassit, and the Technion Research and Development Co. Ltd, as well as in many boards of portfolio companies that Yozma invested in.
Mr. Erlich was the Deputy Chairman of the National Reasearch & Development Council of Israel for two years until 2010 and the Chairman of MATIMOP, a non profit Government Entity for the promotion of industrial R&D; A Board Member (five years) of the Russian Venture Capital Company (RVC), a $1 billion government fund of funds and was a consultant to several governments including New Zealand, S.Korea, Canada, Portugal and Greece.
As of today, Erlich and Yozma is a Venture Capital consulting and investments company in Israel and abroad
Mr. Erlich holds B.Sc.
in Chemistry and an MBA from the Hebrew University of Jerusalem.
Postes actifs de Yigal Erlich
| Sociétés | Poste | Début |
|---|---|---|
The Yozma Group
 The Yozma Group Investment ManagersFinance The Yozma Group (Yozma) is a venture capital firm founded in 1993 by Boaz Goldschmidt and Yigal Erlich. The firm is headquartered in Tel Aviv, Israel with additional offices in Singapore and Korea. | Fondateur | 07/08/2009 |
Clariton Networks Ltd.
 Clariton Networks Ltd. Computer CommunicationsElectronic Technology Clariton Networks develops innovative communications products enabling Cellular, Cable TV (HFC) and Fiber to the Home (FTTH) operators to deliver high quality cellular voice and data traffic to home and other indoor environments. In carrying cellular signals over a fixed infrastructure Clariton's solutions enhance industry trends such as Fixed Mobile Convergence (FMC) and Quad Play. Clariton believes that the most efficient way to enhance in-building cellular coverage is to carry the signal indoors over existing infrastructure such as cable TV HFC, TV coax or FTTH. Leveraging existing assets decreases equipment and installation costs, making projects financially and operationally feasible and ensuring a good ROI. Clariton's products have been commercially deployed with some of the world's leading operators and are the most cost effective means of providing these services utilizing Cable TV and FTTH infrastructure. Clariton Networks is a venture backed company. Clariton was established in 2001, is based in Israel and has offices in the U.S. and the U.K. | Président | - |
Ultrasight
 Ultrasight Packaged SoftwareTechnology Services Ultrasight is an Israeli company that aims to revolutionize cardiac sonography through the power of machine learning to enable more accurate and timely clinical decisions. The company is based in Rehovot, Israel. The company's Ultrasight AI guidance system helps bring the benefits of cardiac imaging to more healthcare professionals in new care settings, allowing patients access to ultrasound anywhere. Ultrasight has achieved CE marking for its real-time guidance software for cardiac ultrasound in the EU, and CA marking in the US. In 2020, Ultrasight won the TCT Innovation Competition, and in 2022, they won the Bristol Myers Squibb Improving Cardiovascular Disease Outcomes Challenge as the most "innovative cardiac technology." Additionally, the company was awarded a patent for its real-time guidance solution for ultrasound devices. The company was founded by Achi Ludomirsky, Itay Kezurer, Yaron Lipman. Davidi Vortman has been the CEO of the company since 2020. | Directeur/Membre du Conseil | - |
Anciens postes connus de Yigal Erlich
| Sociétés | Poste | Fin |
|---|---|---|
Predix Pharmaceuticals Holdings, Inc.
 Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | Directeur/Membre du Conseil | 18/08/2006 |
| Israel Venture Association | Président | - |
| MATIMOP | Président | - |
| HBL - HADASIT BIO-HOLDINGS LTD | Président | - |
Collgard Biopharmaceuticals Ltd.
 Collgard Biopharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Collgard Biopharmaceuticals, the tissue therapeutics company, is developing drug treatments that target disease progression by directly influencing the tissue regeneration process. Central to Collgard's novel approach is its lead drug candidate, Tempostatin (Halofuginone hydrobromide). Tempostatin is a multi-indication, small-molecule drug candidate that has been identified by the company as influencing a 'master switch' in the body's tissue repair process. As a potent and selective regulator of stromal cell activation, cell migration and excessive collagen type I synthesis, Tempostatin makes it possible to harness and direct the tissue repair process for treating diseases acting at the tissue level. Collgard is developing therapeutic solutions for several clinical indications with significant unmet clinical needs. These solutions are based on highly specific control of the tissue repair process. Current programs target the following indications vascular restenosis, end-organ fibrosis, selected cancers and dermal fibroproliferative disorders. Tempostatin holds exceptional promise based on addressing a fundamental underlying pathological process that is not accessible to other current therapeutic approaches. In developing Tempostatin, Collgard seeks to offer novel therapeutic solutions as well as extend the effectiveness of existing therapies. Founded in 1996, Collgard Biopharmaceuticals is a privately held, clinical stage company, led by a global team of medical and drug development experts based in Atlanta and Tel Aviv. Scientific and clinical collaborators include The Mayo Clinic, the U.S. NCI, the EORTC, and Harvard Medical School. Collgard was founded by Medica Venture Partners. Additional investors include Mayo Medical Ventures, Denali Ventures, Yozma Group, and Comsor. | Directeur/Membre du Conseil | - |
Formation de Yigal Erlich
| The Hebrew University of Jerusalem | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HBL - HADASIT BIO-HOLDINGS LTD | Finance |
| Entreprise privées | 7 |
|---|---|
Predix Pharmaceuticals Holdings, Inc.
Predix Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. | Health Technology |
The Yozma Group
The Yozma Group Investment ManagersFinance The Yozma Group (Yozma) is a venture capital firm founded in 1993 by Boaz Goldschmidt and Yigal Erlich. The firm is headquartered in Tel Aviv, Israel with additional offices in Singapore and Korea. | Finance |
Collgard Biopharmaceuticals Ltd.
Collgard Biopharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Collgard Biopharmaceuticals, the tissue therapeutics company, is developing drug treatments that target disease progression by directly influencing the tissue regeneration process. Central to Collgard's novel approach is its lead drug candidate, Tempostatin (Halofuginone hydrobromide). Tempostatin is a multi-indication, small-molecule drug candidate that has been identified by the company as influencing a 'master switch' in the body's tissue repair process. As a potent and selective regulator of stromal cell activation, cell migration and excessive collagen type I synthesis, Tempostatin makes it possible to harness and direct the tissue repair process for treating diseases acting at the tissue level. Collgard is developing therapeutic solutions for several clinical indications with significant unmet clinical needs. These solutions are based on highly specific control of the tissue repair process. Current programs target the following indications vascular restenosis, end-organ fibrosis, selected cancers and dermal fibroproliferative disorders. Tempostatin holds exceptional promise based on addressing a fundamental underlying pathological process that is not accessible to other current therapeutic approaches. In developing Tempostatin, Collgard seeks to offer novel therapeutic solutions as well as extend the effectiveness of existing therapies. Founded in 1996, Collgard Biopharmaceuticals is a privately held, clinical stage company, led by a global team of medical and drug development experts based in Atlanta and Tel Aviv. Scientific and clinical collaborators include The Mayo Clinic, the U.S. NCI, the EORTC, and Harvard Medical School. Collgard was founded by Medica Venture Partners. Additional investors include Mayo Medical Ventures, Denali Ventures, Yozma Group, and Comsor. | Health Technology |
Clariton Networks Ltd.
Clariton Networks Ltd. Computer CommunicationsElectronic Technology Clariton Networks develops innovative communications products enabling Cellular, Cable TV (HFC) and Fiber to the Home (FTTH) operators to deliver high quality cellular voice and data traffic to home and other indoor environments. In carrying cellular signals over a fixed infrastructure Clariton's solutions enhance industry trends such as Fixed Mobile Convergence (FMC) and Quad Play. Clariton believes that the most efficient way to enhance in-building cellular coverage is to carry the signal indoors over existing infrastructure such as cable TV HFC, TV coax or FTTH. Leveraging existing assets decreases equipment and installation costs, making projects financially and operationally feasible and ensuring a good ROI. Clariton's products have been commercially deployed with some of the world's leading operators and are the most cost effective means of providing these services utilizing Cable TV and FTTH infrastructure. Clariton Networks is a venture backed company. Clariton was established in 2001, is based in Israel and has offices in the U.S. and the U.K. | Electronic Technology |
| MATIMOP | Government |
| Israel Venture Association | |
Ultrasight
Ultrasight Packaged SoftwareTechnology Services Ultrasight is an Israeli company that aims to revolutionize cardiac sonography through the power of machine learning to enable more accurate and timely clinical decisions. The company is based in Rehovot, Israel. The company's Ultrasight AI guidance system helps bring the benefits of cardiac imaging to more healthcare professionals in new care settings, allowing patients access to ultrasound anywhere. Ultrasight has achieved CE marking for its real-time guidance software for cardiac ultrasound in the EU, and CA marking in the US. In 2020, Ultrasight won the TCT Innovation Competition, and in 2022, they won the Bristol Myers Squibb Improving Cardiovascular Disease Outcomes Challenge as the most "innovative cardiac technology." Additionally, the company was awarded a patent for its real-time guidance solution for ultrasound devices. The company was founded by Achi Ludomirsky, Itay Kezurer, Yaron Lipman. Davidi Vortman has been the CEO of the company since 2020. | Technology Services |
